Abnormal expression of glucose transporter-1 are a driver of early relapse in follicular lymphoma

ABSTRACT: FL patients with high GLUT1 levels are at increased risk for early relapse and show only limited responses to PI3K inhibitors. The development of new therapies requires an understanding of the changes in their tumor immune microenvironment (TIME). Using novel IMC and proteomics techniques, we comprehensively identified distinguishing features in the TIME as a function of GLUT1 levels. Bioinformatics analyses identified a crosstalk between GLUT1 and TIME in tumor development and suggest that FL patients expressing high GLUT1 may benefit from metabolic-modulating therapies to prevent early relapse.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Lymph Node

DISEASE(S): Lymphoma

SUBMITTER: qingyuan zhang  

LAB HEAD: qingyuan zhang

PROVIDER: PXD031257 | Pride | 2023-03-11

REPOSITORIES: Pride